Hospital-based directly observed therapy for HIV-infected children and adolescents to assess adherence to antiretroviral medications

Pediatrics

Volumn 119, Issue 5, 2007, Pages

  Glikman, Daniel ^a,c   Walsh, Linda ^a   Valkenburg, Judy ^a   Mangat, P Daisy ^a,b   Marcinak, John F ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c Section of Pediatric Endocrinology   (United States)

Author keywords

Adherence; Adolescents; Children; Directly observed therapy; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADOLESCENT; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL CARE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LENGTH OF STAY; MALE; MEDICAL RECORD; OBSERVATIONAL METHOD; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT FAILURE; VIRUS LOAD; VIRUS RESISTANCE;

ADOLESCENT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; DIRECTLY OBSERVED THERAPY; FEMALE; HIV INFECTIONS; HOSPITALS, UNIVERSITY; HUMANS; MALE; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; VIRAL LOAD;

EID: 34248199916     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2006-2614     Document Type: Article

References (21)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860
2. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279:450-454
3. Descamps D, Flandre P, Calvez V, et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. JAMA. 2000;283:205-211
4. Reddington C, Cohen J, Baldillo A, et al. Adherence to medication regimens among children with human immunodeficiency virus infection. Pediatr Infect Dis J. 2000;19:1148-1153
5. Watson DC, Farley JJ. Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J. 1999;18:682-689
6. Ickovics JR, Cameron A, Zackin R, et al. Consequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group Protocol 370. Antivir Ther. 2002;7:185-193
7. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497
8. Shingadia D, Viani RM, Yogev R, et al. Gastrostomy tube insertion for improvement of adherence to highly active antiretroviral therapy in pediatric patients with human immunodeficiency virus. Pediatrics. 2000;105(6). Available at: www.pediatrics.org/cgi/content/full/105/6/e80
9. Roberts GM, Wheeler JG, Tucker NC, et al. Nonadherence with pediatric human immunodeficiency virus therapy as medical neglect. Pediatrics. 2004;114:346-353
10. Simoni JM, Frick PA, Pantalone DW, Turner BJ. Antiretroviral adherence interventions: a review of current literature and ongoing studies. Top HIV Med. 2003;11:185-198
11. Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis: consensus statement of the public health tuberculosis guidelines panel. JAMA. 1998;279:943-948
12. Mitty JA, Stone VE, Sands M, Macalino G, Flanigan T. Directly observed therapy for the treatment of people with human immunodeficiency virus infection: a work in progress. Clin Infect Dis. 2002;34:984-990
13. Mitty JA, Flanigan TP. Community-based interventions for marginalized populations. Clin Infect Dis. 2004;38:S373-S375
14. Gigliotti F, Murante BL, Weinberg GA. Short course directly observed therapy to monitor compliance with antiretroviral therapy in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2001;20:716-718
15. Parsons GN, Siberry GK, Parsons JK, et al. Multidisciplinary, inpatient directly observed therapy for HIV-1-infected children and adolescents failing HAART: a retrospective study. AIDS Patient Care STDS. 2006;20:275-284
16. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Available at: http://aidsinfo.nih.gov. Accessed August 10, 2006
17. Bartlett JA, DeMasi R, Dawson D, Hill A. Variability in repeated consecutive measurements of plasma human immunodeficiency virus RNA in persons receiving stable nucleoside reverse transcriptase inhibitor therapy or no treatment. J Infect Dis. 1998;178:1803-1805
18. Flynn PM, Rudy BJ, Douglas SD, et al. Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy. J Infect Dis. 2004;190:271-279
19. Palumbo PE, Raskino C, Fiscus S, et al. Predictive value of quantitative plasma HIV RNA and CD4 lymphocyte count in HIV-infected infants and children. JAMA. 1998;279:756-761
20. Gibb DM, Duong T, Leclezio VA, Walker AS, Verweel G, Dunn DT. Immunologic changes during unplanned treatment interruptions of highly active antiretroviral therapy in children with human immunodeficiency virus type 1 infection. Pediatr Infect Dis J. 2004;23:446-450
21. Borkowsky W, Stanley K, Douglas SD, et al. Immunologic response to combination nucleoside analogue plus protease inhibitor therapy in stable antiretroviral therapy-experienced human immunodeficiency virus-infected children. J Infect Dis. 2000;182:96-103